Trial proves new osteoporosis treatment

November 7, 1997

DRUGS that reduce the risk of women with osteoporosis suffering bone fractures have been successfully trialled by the University of Plymouth. Osteoporosis, which weakens bones, usually occurs after menopause through loss of the female hormone oestrogen, and is normally treated with hormone replacement therapy. Plymouth led comprehensive worldwide trials of Alendronate, a non-hormonal drug first trialled in 1996, and found that it significantly replaced lost bone after 12 months, with no major side effects, cutting the risk of fracture by as much as half.

Please login or register to read this article

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments

Have your say

Log in or register to post comments